News
ABIO
3.290
+0.92%
0.030
Weekly Report: what happened at ABIO last week (0422-0426)?
Weekly Report · 5d ago
ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024
ARCA biopharma reported earnings per share of -14 cents for the first quarter of 2024. The company did not report any revenue for the quarter. ARCA bipharma just reported results for first quarter 2024. The company reported no revenue for that quarter.
Investorplace · 04/26 01:55
ARCA biopharma GAAP EPS of -$0.14
Seeking Alpha · 04/25 21:17
ARCA biopharma Q1 EPS $(0.14) Down From $(0.09) YoY
Benzinga · 04/25 20:48
ARCA BIOPHARMA INC- QTRLY NET LOSS 0.14 PER BASIC AND DILUTED SHARE
Reuters · 04/25 20:15
Press Release: ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update. ARCA and Oruka Therapeutics announce Merger Agreement to merge on April 3, 2024. The Company is a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases. Thomas Keuer appointed as President of ARCA.
Dow Jones · 04/25 20:15
*ARCA biopharma 1Q Loss $2.01M >ABIO
Dow Jones · 04/25 20:15
*ARCA biopharma 1Q Loss/Shr 14c >ABIO
Dow Jones · 04/25 20:15
Press Release: ARCA biopharma Announces First -2-
This press release contains "forward-looking statements" concerning the proposed merger between ARCA and Oruka. No Offer or Solicitation is intended to be made. This press release does not constitute an offer to sell or a solicitation of a proxy for the Proposed Transactions.
Dow Jones · 04/25 20:15
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
Barchart · 04/25 15:15
Arca Biopharma Increases Executive Retention Bonuses
TipRanks · 04/23 20:32
Weekly Report: what happened at ABIO last week (0415-0419)?
Weekly Report · 04/22 12:22
Weekly Report: what happened at ABIO last week (0408-0412)?
Weekly Report · 04/15 12:12
Weekly Report: what happened at ABIO last week (0401-0405)?
Weekly Report · 04/08 12:18
ARCA biopharma 13D Filing Shows Adage Capital Management, L.P. Reported A 8.28% Stake In The Co As Of April 3, 2024
Benzinga · 04/05 20:17
ADAGE CAPITAL MANAGEMENT, L.P. REPORTS 8.28% STAKE IN ARCA BIOPHARMA AS OF APRIL 3- SEC FILING
Reuters · 04/05 20:16
ARCA Biopharma stock drops on CEO departure
ARCA Biopharma shares down about 7% premarket after company and CEO Michael Bristow mutually agreed to conclude Bristow’s employment and service as a director. The Board appointed Thomas Keuer to serve as ARCA's President and principal executive officer. ARCA biopharma stock drops on CEO departure.
Seeking Alpha · 04/05 13:06
Altice USA, Genfit, Brooge Energy among premarket losers' pack
On the Move: Altice USA, Genfit, Brooge Energy among premarket losers' pack. HWH International, ARCA biopharma, ZCMD, HWH among the biggest morning stock movers. ATUS, GNFT, BROG and HWH are among the morning's biggest losers.
Seeking Alpha · 04/05 12:29
ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed merger of ARCA biopharma, Inc. And Oruka Therapeutics. KSF is seeking to determine whether the merger is fair to ARCA shareholders.
Barchart · 04/05 12:27
Arca Biopharma Announces Executive Leadership Transition
TipRanks · 04/04 20:43
More
Webull provides a variety of real-time ABIO stock news. You can receive the latest news about Arca Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABIO
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.